Human Biology Division, Fred Hutch
Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch
Dr. Behnam Nabet is a cancer chemical biologist who develops cutting-edge technologies to target key cancer-causing proteins. Rather than block or disable a protein, Nabet focuses his studies on developing strategies that exploit the cell’s mechanisms for degrading proteins to eliminate cancer-causing proteins with speed and precision. These innovative technologies identify promising drug candidates and deepen our understanding of the molecular circuits that are critical for cancer cell growth and survival. Nabet also works to adapt this approach into therapeutic strategies to deliver new solutions for cancers that resist current therapies.
Postdoctoral Fellowship, Dana-Farber Cancer Institute, Harvard Medical School, 2021
PhD, Northwestern University, 2015
BA, University of Pennsylvania, 2007
The Nabet lab is dedicated to targeting oncogenic signaling networks through control of protein homeostasis to advance new therapeutic strategies in cancer. We use multidisciplinary approaches including development of degradation-based technologies to discover, validate, and gain insights into clinically relevant targets. We believe in collaborative and open-source science and are committed to supporting the next-generation of scientists.
The current goals in the Nabet lab are to: (1) target vulnerabilities nominated from functional genetic approaches that promote resistance to cancer therapeutics to elucidate translationally relevant combination treatment approaches; (2) establish the clinical potential of targeted protein degradation using small molecule degraders; and (3) expand the spectrum of proximity-induced interactions that can modulate protein activity to activate target proteins.
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210